pA2 online
© Copyright 2004 The British Pharmacological Society

002P University of Newcastle
Winter Meeting December 2004

Δ9 -tetrahydrocannabinol (THC) antagonises the vasorelaxant effects of anandamide in rat isolated mesenteric arteries

Saoirse E. O’Sullivan, David A. Kendall and Michael D. Randall. School of Biomedical Sciences, University of Nottingham, Queen’s Medical Centre, Nottingham NG7 2UH.

Print abstract

Search PubMed for:

O’Sullivan SE

Kendall DA

Randall MD

Individually, both THC and anandamide cause vasorelaxation in rat mesenteric arteries. However, the interactions between exogenous and endogenous cannabinoids are still largely unknown, and evidence suggests that THC may act as an antagonist to other cannabinoid molecules (Bayewitch et al., 1996; Kelley & Thayer, 2004). We have therefore examined the effects of THC on vasorelaxation to anandamide.

Male Wistar rats (200-300 g) were killed by cervical dislocation. Small mesenteric resistance arteries (G3) or the superior mesenteric artery (G0) were isolated, cut into 2 mm lengths and mounted on a Mulvany-Halpern myograph. Vessels were bathed in oxygenated Krebs’ solution at 37oC. Vessels were set to a baseline tone of 5 mN, and U46619 was added to increase tension by at least 5 mN.

THC caused significant rightward shifts in the concentration-response curve to anandamide in G3 vessels at 1 µM (control pEC50 = 6.43 ± 0.22, mean ± SEM, n=8 cf pEC50 = 5.09 ± 0.57, n=8, P<0.05, ANOVA) and 10 µM (pEC50 = 4.49 ± 0.20, n=6, P<0.01). THC (10 µM) did not affect the concentration-response curve to the non-cannabinoid vasorelaxant, verapamil (control pEC50 = 7.01 ± 0.12, n=5; & THC 10 µM pEC50 = 7.22 ± 0.09, n=6), the vanilloid receptor agonist capsaicin (capsaicin pEC50 = 5.37 ± 0.11, n=5; & THC 10µM pEC50 = 5.45 ± 0.08, n=4), or the CB1 receptor agonist CP 55,940 (CP 55,940 pEC50 = 5.86 ± 0.09, n=5; & THC 10 µM pEC50 = 5.77 ± 0.18, n=5). THC (10 µM) also did not affect the actions of anandamide in the superior mesenteric artery (G0; control pEC50 = 5.39 ± 0.29, n=7; & THC 10 µM pEC50 = 5.44 ± 0.34, n=7). When THC (10 µM) was applied in combination with endothelial-denudation in G3 vessels, THC did not significantly inhibit the vasorelaxant effects of anandamide further than was seen with denudation alone (denuded vessels pEC50 = 5.28 ± 0.29, n=7; denuded vessels & THC 10 µM pEC50 = 4.25 ± 0.59, n=6). The inhibitory effect of 1 µM THC on vasorelaxation to anandamide was significantly enhanced in the presence of L-NAME (THC 1 µM pEC50 = 5.59 ± 0.13, n=8; THC 1 µM & L-NAME pEC50 = 3.22 ± 0.93, n=5, P<0.05). The magnitude and duration of vasorelaxation to carbachol (10 µM) in the presence of indomethacin (10 µM) and L-NAME (300 µM) (mediated by endothelium-derived hyperpolarising factor (EDHF)) was also significantly reduced in the presence of THC (10 µM or 100 µM). The effects of THC were similar in profile to the effects of the gap junction inhibitor, 18 -glycyrrhetinic acid (18-GA, 100 µM).

In summary, THC inhibits the vasorelaxant activities of the endogenous cannabinoid anandamide in small isolated mesenteric arteries. This is not through non-specific actions, or actions at the vanilloid receptor or CB1 receptor, but possibly through inhibition of EDHF activity via inhibition of intercellular communication.

Bayewitch et al. (1996). J. Biol. Chem.,271, 9902-99055.
Kelley & Thayer (2004). Neuropharmacology.,46, 709-715.

This study was funded by the British Heart Foundation (PG2001/150).